RT Journal Article
SR Electronic
T1 Update on biology and management of mesothelioma
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 200226
DO 10.1183/16000617.0226-2020
VO 30
IS 159
A1 Rachelle Asciak
A1 Vineeth George
A1 Najiib M. Rahman
YR 2021
UL http://err.ersjournals.com/content/30/159/200226.abstract
AB Malignant pleural mesothelioma is an aggressive, incurable cancer that is usually caused by asbestos exposure several decades before symptoms arise. Despite widespread prohibition of asbestos production and supply, its incidence continues to increase. It is heterogeneous in its presentation and behaviour, and diagnosis can be notoriously difficult. Identification of actionable gene mutations has proven challenging and current treatment options are largely ineffective, with a median survival of 10–12 months.However, the past few years have witnessed major advances in our understanding of the biology and pathogenesis of mesothelioma. This has also revealed the limitations of existing diagnostic algorithms and identified new treatment targets.Recent clinical trials have re-examined the role of surgery, provided new options for the management of associated pleural effusions and heralded the addition of targeted therapies. The increasing complexity of mesothelioma management, along with a desperate need for further research, means that a multidisciplinary team framework is essential for the delivery of contemporary mesothelioma care.This review provides a synthesised overview of the current state of knowledge and an update on the latest research in the field.Despite a better understanding of the pathogenesis of malignant pleural mesothelioma, effective treatment that prolongs survival significantly is lacking. Ongoing research may identify select patient groups that may benefit from surgical treatment. https://bit.ly/3k16J9O